Renal cell carcinoma in chronic hemodialysis patients. A 1990 questionnaire study and review of past questionnaires.

Isao IshikawaJournal of Japanese Society for Dialysis Therapy 1991 · DOI

Abstract

In February 1990, a nationwide questionnaire-based survey was conducted across 2,030 dialysis centers in Japan to investigate the incidence and characteristics of renal cell carcinoma (RCC) in patients undergoing chronic hemodialysis. The survey, which achieved a 64% response rate, identified 130 new cases of RCC. The average patient age was 52.6 years, with a mean dialysis duration of 106 months. A significant majority of cases (82.3%) were associated with Acquired Renal Cystic Disease (ARCD). Notably, screening via CT and ultrasound accounted for the vast majority of diagnoses, while symptomatic cases were rare. Comparison with historical data from 1982–1988 revealed that RCC in non-ARCD patients tends to occur in older individuals with shorter dialysis durations and carries a significantly higher risk of metastasis compared to ARCD-associated RCC.

Introduction

Patients undergoing long-term hemodialysis are known to develop Acquired Renal Cystic Disease (ARCD), a condition where non-functioning kidneys develop multiple cysts. By the late 1980s, it became increasingly clear that ARCD serves as a significant risk factor for the development of renal cell carcinoma (RCC). This study aimed to quantify the prevalence, clinical characteristics, and prognosis of RCC within the Japanese dialysis population, providing a critical update to biennial surveys initiated in 1982.

Methods

The researchers utilized a nationwide survey sent to 2,030 dialysis units in Japan. Data points included patient demographics, primary kidney disease, diagnostic methods, tumor size, presence of ARCD, and clinical outcomes. The 1990 data (130 cases) were analyzed both independently and as part of a larger aggregate of 364 cases collected since 1982. Statistical significance was evaluated using t-tests and Chi-square tests to compare subgroups, particularly focusing on the presence or absence of ARCD.

Key Insights and Clinical Characteristics

The Role of Proactive Screening

A primary finding of the 1990 survey was the overwhelming success of routine screening. Approximately 88% of cases were detected through imaging (CT scans and ultrasound) rather than clinical symptoms. This underscores the fact that RCC in the dialysis population is largely asymptomatic until advanced stages, making regular imaging the only reliable method for early detection.

Distribution of diagnostic methods showing the dominance of CT and Ultrasound over symptomatic presentation.

The ARCD Connection and Metastatic Risk

The study identified a clear clinical distinction between two types of dialysis-related RCC based on the presence of ARCD. Cancers arising in kidneys with ARCD (82.3% of cases) typically occurred in younger patients with longer dialysis histories. Conversely, RCC in non-ARCD kidneys occurred in older patients with shorter dialysis durations. Crucially, the metastatic rate was significantly higher in the non-ARCD group (27.4%) compared to the ARCD group (13.6%), suggesting a more aggressive biological profile or later detection in the absence of cystic disease.

Comparison of metastasis rates between ARCD+ and ARCD- patients, showing a significantly higher rate in the non-ARCD group.

Key Results

  • Incidence: The incidence of RCC in dialysis patients was calculated at 125 per 100,000, approximately 41 times higher than the general Japanese population at the time (3 per 100,000).
  • Demographics: The average patient was 52.6 years old with a 6.2:1 male-to-female ratio. The mean duration of dialysis was 8.8 years.
  • Tumor Characteristics: The mean tumor diameter was 4.2 cm. Bilateral tumors were found in 8.5% of cases, a rate significantly higher than in the general population.
  • Outcomes: Curative nephrectomy was successful in 76.7% of the 1990 cohort. Overall, 15.1% of patients presented with metastatic disease at diagnosis.

Conclusion

The 1990 survey highlights a dramatic increase in the identified cases of RCC among hemodialysis patients, likely due to both an aging dialysis population and improved screening protocols. The strong association between ARCD and RCC, combined with the high incidence rate, mandates rigorous, lifelong radiological follow-up for all chronic dialysis patients. Future research should focus on the long-term survival benefits of early detection and the potential for secondary primary cancers in the remaining kidney.

Summary updated

BibTeX
@article{ishikawa1991renal,
  author = {Isao Ishikawa},
  title = {{Renal cell carcinoma in chronic hemodialysis patients. A 1990 questionnaire study and review of past questionnaires.}},
  journal = {Journal of Japanese Society for Dialysis Therapy},
  year = {1991},
  doi = {10.4009/jsdt1985.24.493},
}
Figure